Moreover, further analysis combined with an independent anti-PD-1 treatment cohort revealed that activation of the MAPK7-NFKB signaling pathway may facilitate T-cell recruitment to the tumor microenvironment and enhance the sensitivity of patients to immunotherapy; on the other hand, PRKDC may reduce the sensitivity of melanoma patients to immunotherapy by increasing DNA damage and enhancing tumor cell proliferation. The gene discussed is PDCD1; the disease is melanoma.